Abstract
Post translational modification of histones and non-histone proteins by acetylation play a key role in tumourigenesis. Histone deacetylases (HDACs) are enzymes involved in remodelling of chromatin by deacetylating the lysine residues and play a pivotal role in epigenetic regulation of gene expression. An aberrant activity of HDACs has been documented in several types of cancers and HDACs have emerged as an attractive therapeutic target. HDAC inhibitors (HDACi) are a structurally diverse group of anti-cancer agents which have a potential role in regulation of gene expression and induction of cell death, cell cycle arrest, and differentiation by altering the acetylation status of histone and non-histone proteins. HDACi have pleiotropic effects on malignant cells and have demonstrated potent anti-cancer activity in pre-clinical studies. A number of clinical trials of HDACi as a monotherapy and/or in combination with conventional and novel chemotherapeutic drugs in solid and haematologic tumours have been published with variable efficacy.
Keywords: Cancer, epigenetics, histone deacetylases, HDAC, HDACi, histone deacetylase inhibitors, vorinostat, romidepsin, belinostat
Current Medicinal Chemistry
Title: Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Volume: 18 Issue: 11
Author(s): B. Venugopal and T.R.J. Evans
Affiliation:
Keywords: Cancer, epigenetics, histone deacetylases, HDAC, HDACi, histone deacetylase inhibitors, vorinostat, romidepsin, belinostat
Abstract: Post translational modification of histones and non-histone proteins by acetylation play a key role in tumourigenesis. Histone deacetylases (HDACs) are enzymes involved in remodelling of chromatin by deacetylating the lysine residues and play a pivotal role in epigenetic regulation of gene expression. An aberrant activity of HDACs has been documented in several types of cancers and HDACs have emerged as an attractive therapeutic target. HDAC inhibitors (HDACi) are a structurally diverse group of anti-cancer agents which have a potential role in regulation of gene expression and induction of cell death, cell cycle arrest, and differentiation by altering the acetylation status of histone and non-histone proteins. HDACi have pleiotropic effects on malignant cells and have demonstrated potent anti-cancer activity in pre-clinical studies. A number of clinical trials of HDACi as a monotherapy and/or in combination with conventional and novel chemotherapeutic drugs in solid and haematologic tumours have been published with variable efficacy.
Export Options
About this article
Cite this article as:
Venugopal B. and Evans T.R.J., Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics, Current Medicinal Chemistry 2011; 18 (11) . https://dx.doi.org/10.2174/092986711795471284
DOI https://dx.doi.org/10.2174/092986711795471284 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Chronic Heart Failure and Exercise Intolerance: The Hemodynamic Paradox
Current Cardiology Reviews Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry ROS Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?
Mini-Reviews in Medicinal Chemistry Meet the Editorial Board
Current Drug Targets Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters